Arteid Memaj

1.0k total citations · 1 hit paper
17 papers, 283 citations indexed

About

Arteid Memaj is a scholar working on Oncology, Surgery and Genetics. According to data from OpenAlex, Arteid Memaj has authored 17 papers receiving a total of 283 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Surgery and 6 papers in Genetics. Recurrent topics in Arteid Memaj's work include Cancer Immunotherapy and Biomarkers (6 papers), Inflammatory Bowel Disease (6 papers) and Microscopic Colitis (3 papers). Arteid Memaj is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Inflammatory Bowel Disease (6 papers) and Microscopic Colitis (3 papers). Arteid Memaj collaborates with scholars based in United States, Canada and Italy. Arteid Memaj's co-authors include Massimo Aglietta, Ka Yeung Mark Wong, Ming Lei, Bart Neyns, Sara Lonardi, Eric Van Cutsem, Alain Hendlisz, Michael J. Overman, Fabio Gelsomino and Sandzhar Abdullaev and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Arteid Memaj

15 papers receiving 273 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

2022 154 citations Thierry André, Sara Lonardi et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Arteid Memaj

Since Specialization

Citations

This map shows the geographic impact of Arteid Memaj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arteid Memaj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arteid Memaj more than expected).

Fields of papers citing papers by Arteid Memaj

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arteid Memaj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arteid Memaj. The network helps show where Arteid Memaj may publish in the future.

Co-authorship network of co-authors of Arteid Memaj

This figure shows the co-authorship network connecting the top 25 collaborators of Arteid Memaj. A scholar is included among the top collaborators of Arteid Memaj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arteid Memaj. Arteid Memaj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Integrated efficacy and safety analysis of mavacamten monotherapy in patients with obstructive hypertrophic cardiomyopathy 2025 ·European Heart Journal ·Iacopo Olivotto, Pablo García‐Pavía, Zhuang Tian, Anjali Owens, Neal K. Lakdawala, Ganesh Balaratnam, (unknown), Arteid Memaj, Yu Chen Barrett, Milind Y. Desai	1
2	Safety and efficacy of apixaban thrombosis prevention in pediatric patients with obesity and acute lymphoblastic leukemia 2025 ·Blood Advances ·Vilmarie Rodriguez, (unknown), Etan Orgel, (unknown), Adam J. Esbenshade, Arteid Memaj, (unknown), (unknown), Lesley Mitchell	0
3	P585 Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North study 2023 ·Journal of Crohn s and Colitis ·Séverine Vermeire, Bincy Abraham, Brian Bressler, Walter Reinisch, (unknown), Arteid Memaj, (unknown), (unknown), Mark T. Osterman, James B. Canavan, B E Sands	0
4	Apixaban Is Effective and Safe in Reducing Venous Thromboembolism (VTE) in Obese Patients with Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (ALL/LL) a Sub-Study Analysis of the Prevapix-ALL/Children's Oncology Group ACCL1333 Trial 2023 ·Blood ·Vilmarie Rodriguez, Sarah H. O’Brien, Glen Lew, Etan Orgel, Kimberly Derr, Mark Ranalli, (unknown), Adam J. Esbenshade, Arteid Memaj, (unknown), (unknown), Lesley Mitchell	2
5	P100 Efficacy and safety of ozanimod in older patients with ulcerative colitis (UC): post hoc analysis of the True North study 2023 ·Poster presentations ·(unknown), Peter M. Irving, Ashwin N. Ananthakrishnan, Irina Blumenstein, Sara N. Horst, (unknown), (unknown), (unknown), (unknown), Arteid Memaj, Nabeel Khan	1
6	Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 breakdown → 2022 ·Annals of Oncology ·Thierry André, Sara Lonardi, Ka Yeung Mark Wong, H.J. Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Sandzhar Abdullaev, Arteid Memaj, Ming Lei, Michael F. Dixon, Scott Kopetz, Michael J. Overman	154
7	Tu1450: EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY 2022 ·Gastroenterology ·Remo Panaccione, Anita Afzali, David Hudesman, Garrett Lawlor, Mark T. Osterman, (unknown), Arteid Memaj, Miguel Regueiro, Subrata Ghosh	5
8	S811 Evaluation of Ozanimod Efficacy and Safety in Older Patients With Ulcerative Colitis: Post Hoc Analysis From the Phase 3 True North Study 2022 ·The American Journal of Gastroenterology ·Nabeel Khan, Peter M. Irving, Irina Blumenstein, Sara N. Horst, (unknown), (unknown), (unknown), (unknown), Arteid Memaj, Ashwin N. Ananthakrishnan	2
9	969: RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY 2022 ·Gastroenterology ·Anita Afzali, Michael Chiorean, Garrett Lawlor, Mark T. Osterman, (unknown), Arteid Memaj, Remo Panaccione, Subrata Ghosh	2
10	DOP43 Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North 2022 ·Journal of Crohn s and Colitis ·Britta Siegmund, Jordan E. Axelrad, (unknown), Mark T. Osterman, (unknown), Arteid Memaj, Miguel Regueiro, Alessandro Armuzzi, Anita Afzali	5
11	SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 2021 ·Annals of Oncology ·Thierry André, Sara Lonardi, Ka Yeung Mark Wong, Heinz‐Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Sandzhar Abdullaev, Arteid Memaj, Ming Lei, Scott Kopetz, Michael J. Overman	7
12	First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. 2021 ·Journal of Clinical Oncology ·Martin Reck, Tudor–Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Żurawski, J. Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Óscar Juan, (unknown), Hiroshi Sakai, Arnaud Scherpereel, Shun Lu, Luis Paz‐Ares, David P. Carbone, Arteid Memaj, S. Marimuthu, Phuong Tran, Thomas John	13
13	Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update. 2021 ·Journal of Clinical Oncology ·Heinz‐Josef Lenz, Sara Lonardi, Vittorina Zagonel, Eric Van Cutsem, María Luisa Limón, Ka Yeung Mark Wong, Alain Hendlisz, Massimo Aglietta, Pilar García‐Alfonso, Bart Neyns, Gabriele Luppi, Dana B. Cardin, Tomislav Dragovich, Usman Shah, Jing Yang, Arteid Memaj, Michael J. Overman	14
14	Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227. 2021 ·Journal of Clinical Oncology ·Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabé, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Adam Płużański, Suresh S. Ramalingam, Julie R. Brahmer, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Judith Bushong, Phuong Tran, Martin Reck	17
15	First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649. 2021 ·Journal of Clinical Oncology ·Markus Moehler, Kohei Shitara, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, (unknown), Tianshu Liu, Michael Schenker, Patricio Yañez, Mustapha Tehfé, Mingshun Li, Dana Cullen, Arteid Memaj, Ming Lei, Hong Xiao, Yelena Y. Janjigian, Jaffer A. Ajani	12
16	The Effect of Frailty on Walking Recovery After Hip Fracture: A Secondary Analysis of the Community Ambulation Project 2021 ·The Journals of Gerontology Series A ·Kathleen K Mangione, Rebecca L. Craik, Rose Anne Kenny, Arteid Memaj, M. F. Miller, (unknown), (unknown), Denise Orwig, Jay Magaziner	9
17	Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040. 2021 ·Journal of Clinical Oncology ·Anthony B. El-Khoueiry, Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming‐Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El‐Rayes, Mirelis Acosta-Rivera, Ho Yeong Lim, Arteid Memaj, Ashwin R. Sama, Chiun Hsu	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact